Search

Your search keyword '"Hebraud, Benjamin"' showing total 50 results
Start Over Author "Hebraud, Benjamin"
50 results on '"Hebraud, Benjamin"'

2. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Author

Roussel, Murielle, Lauwers-Cances, Valérie, Macro, Margaret, Leleu, Xavier, Royer, Bruno, Hulin, Cyrille, Karlin, Lionel, Perrot, Aurore, Touzeau, Cyrille, Chrétien, Marie-Lorraine, Rigaudeau, Sophie, Dib, Mamoun, Nicolas-Virelizier, Emmanuelle, Escoffre-Barbe, Martine, Belhadj, Karim, Mariette, Clara, Stoppa, Anne-Marie, Araujo, Carla, Doyen, Chantal, Fontan, Jean, Kolb, Brigitte, Garderet, Laurent, Brechignac, Sabine, Malfuson, Jean-Valère, Jaccard, Arnaud, Lenain, Pascal, Borel, Cécile, Hebraud, Benjamin, Benbrahim, Omar, Dorvaux, Véronique, Manier, Salomon, Augeul-Meunier, Karine, Vekemans, Marie-Christiane, Randriamalala, Edouard, Chaoui, Driss, Caers, Jo, Chaleteix, Carine, Benboubker, Lofti, Vincent, Laure, Glaisner, Sylvie, Zunic, Patricia, Slama, Borhane, Eveillard, Jean-Richard, Humbrecht-Kraut, Catherine, Morel, Véronique, Mineur, Philippe, Eisenmann, Jean-Claude, Demarquette, Hélène, Richez, Valentine, Vignon, Marguerite, Caillot, Denis, Facon, Thierry, Moreau, Philippe, Colin, Anne-Laurène, Olivier, Pascale, Wuilleme, Soraya, Avet-Loiseau, Hervé, Corre, Jill, and Attal, Michel

Published
2022
Full Text
View/download PDF

3. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

Author

Facon, Thierry, Cook, Gordon, Usmani, Saad Z., Hulin, Cyrille, Kumar, Shaji, Plesner, Torben, Touzeau, Cyrille, Bahlis, Nizar J., Basu, Supratik, Nahi, Hareth, Goldschmidt, Hartmut, Quach, Hang, Mohty, Mohamad, Venner, Christopher P., Weisel, Katja, Raje, Noopur, Hebraud, Benjamin, Belhadj-Merzoug, Karim, Benboubker, Lotfi, Decaux, Olivier, Manier, Salomon, Caillot, Denis, Ukropec, Jon, Pei, Huiling, Van Rampelbergh, Rian, Uhlar, Clarissa M., Kobos, Rachel, and Zweegman, Sonja

Published
2022
Full Text
View/download PDF

4. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial

Author

Roussel, Murielle, Moreau, Philippe, Hebraud, Benjamin, Laribi, Kamel, Jaccard, Arnaud, Dib, Mamoun, Slama, Borhane, Dorvaux, Véronique, Royer, Bruno, Frenzel, Laurent, Zweegman, Sonja, Klein, Saskia K, Broijl, Annemiek, Jie, Kon-Siong, Wang, Jianping, Vanquickelberghe, Veronique, de Boer, Carla, Kampfenkel, Tobias, Gries, Katharine S, Fastenau, John, and Sonneveld, Pieter

Published
2020
Full Text
View/download PDF

5. Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

Author

Rosiñol, Laura, primary, Hebraud, Benjamin, additional, Oriol, Albert, additional, Colin, Anne-Laurène, additional, Ríos Tamayo, Rafael, additional, Hulin, Cyrille, additional, Blanchard, María Jesús, additional, Caillot, Denis, additional, Sureda, Anna, additional, Hernández, Miguel Teodoro, additional, Arnulf, Bertrand, additional, Mateos, Maria-Victoria, additional, Macro, Margaret, additional, San-Miguel, Jesús, additional, Belhadj, Karim, additional, Lahuerta, Juan José, additional, Garelik, M. Brigid, additional, Bladé, Joan, additional, and Moreau, Philippe, additional

Published
2023
Full Text
View/download PDF

6. The CARMEN-France registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France

Author

Ackermann, Felix, Adoue, Daniel, Alexandra, Jean-François, Alric, Laurent, Andre, Baptiste, Arista, Sophie, Astudillo, Leonardo, Audia, Sylvain, Badet, Françoise, Balardy, Laurent, Berezne, Alice, Bonmati, Caroline, Bonnet, Delphine, Borel, Cécile, Bories, Eva, Bouillet, Laurence, Boutboul, David, Branco, Benoit, Brechemier, Delphine, Briantais, Antoine, Brun, Natacha, Carreiro, Miguel, Castel, Brice, Cathebras, Pascal, Catros, Florian, Caubet, Olivier, Caudrelier, Léo, Chaminade, Axel, Chauveheid, Marie-Paul, Cheze, Stéphane, Chezel, Julie, Clement, Mélissa, Comont, Thibault, Corvilain, Emilie, Cougoul, Pierre, Courtault, Carine, Crickx, Etienne, Damian, Louise, De Almeida, Sébastien, de Sainte Marie, Benjamin, Decker, Paul, Deibener-Kaminsky, Joëlle, Delavigne, Karen, Delbrel, Xavier, Denis, Guillaume, Deshayes, Samuel, Dingremont, Claire, Dion, Jérémie, Dossier, Antoine, Duffau, Pierre, Dumont, Anne, Dupont, Romain, Durand, Jean-Marc, Ebbo, Mikael, Eshagh, Deborah, Fadlallah, Jehane, Farhat, Meryem, Faucher, Benoit, Faurie, Pierre, Faurie, Thomas, Fieschi, Claire, Galicier, Lionel, Garric, Marie, Gaudin, Clément, Gauthier, Martin, Gerfaud-Valentin, Mathieu, Ghrenassia, Etienne, Giraud, Jean-Thomas, Gobert, Delphine, Godel-Labouret, Aurélie, Goulenok, Tiphaine, Gourguechon, Clément, Goursaud, Laure, Graveleau, Julie, Grobost, Vincent, Guilpain, Philippe, Hadj-Khelifa, Sondess, Harle, Jean-Robert, Hebraud, Benjamin, Hennique, Hélène, Hot, Arnaud, Issaka, Ismaël, Jaussaud, Roland, Jean, Estelle, Jeandel, Pierre-Yves, Khatibi, Sarah, Kouchit, Yanis, Laribi, Kamel, Lazareth, Anne, Lechtman, Sarah, Leguenno, Guillaume, Lemeu, Mélanie, Lemonnier, Margaux, Leplay, Lorraine, Leveneur, Yann, Levraut, Michael, Lifermann, François, Limal, Nicolas, Lioger, Bertrand, Lobbes, Hervé, Loustau, Valentine, Machelart, Irène, Madaule, Serge, Mahevas, Matthieu, Maigne, Gwenola, Malphettes, Marion, Maquet, Julien, Martin-Blondel, Guillaume, Martis, Nihal, Merckx, Antoine, Michaud, Martin, Mohamed, Shirine, Moignet-Autrel, Aline, Montes, Lydia, Moulinet, Thomas, Mourguet, Morgane, Nuccio, Fanny, Orvain, Corentin, Pan Petesch, Brigitte, Papo, Thomas, Paricaud, Kim, Pastissier, Andréa, Perard, Laurent, Piel-Julian, Marie-Léa, Pinede, Laurent, Pontille, Fabien, Prudhomme, Laurent, Pugnet, Grégory, Quinquenel, Anne, Rauzy, Odile, Recher, Christian, Remy, Véronique, Reynaud, Quitterie, Rieu, Virginie, Rigal, Florence, Rispal, Patrick, Rivet, Valérian, Robbins, Ailsa, Rohmer, Julien, Roumier, Mathilde, Ruivard, Marc, Saada, Noemie, Sacre, Karim, Sailler, Laurent, Saint-Lezer, Arnaud, Saunier, Aurélie, Sauvetre, Gaetan, Schleinitz, Nicolas, Seguier, Julie, Sire, Stéphane, Soubrier, Caroline, Swiader, Laure, Tavitian, Suzanne, Terriou, Louis, Thomazeau, Josephine, Toledano, Albanie, Urbanski, Geoffrey, Veit, Véronique, Versini, Mathilde, Viallard, Jean-François, Walter, Ondine, Moulis, Guillaume, Michel, Marc, Bonnotte, Bernard, and Godeau, Bertrand

Published
2024
Full Text
View/download PDF

7. P891: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RRMM PATIENTS: RESULTS OF THE MULTICENTER PHASE 2 STUDY (IFM 2018-02) OF THE INTERGROUPE FRANCOPHONE DU MYÉLOME (IFM).

Author

Macro, Margaret, primary, Touzeau, Cyrille, additional, Mariette, Clara, additional, Manier, Salomon, additional, Brechignac, Sabine, additional, Vincent, Laure, additional, Hebraud, Benjamin, additional, Decaux, Olivier, additional, Schulmann, Samantha, additional, Lenoir, Caroline, additional, Godmer, Pascal, additional, Farge, Agathe, additional, Paul, Laure Peyro Saint, additional, Parienti, Jean-Jacques, additional, and Leleu, Xavier, additional

Published
2023
Full Text
View/download PDF

9. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

Author

Chretien, Marie-Lorraine, Corre, Jill, Lauwers-Cances, Valerie, Magrangeas, Florence, Cleynen, Alice, Yon, Edwige, Hulin, Cyrille, Leleu, Xavier, Orsini-Piocelle, Frederique, Blade, Jean-Sebastien, Sohn, Claudine, Karlin, Lionel, Delbrel, Xavier, Hebraud, Benjamin, Roussel, Murielle, Marit, Gerald, Garderet, Laurent, Mohty, Mohamad, Rodon, Philippe, Voillat, Laurent, Royer, Bruno, Jaccard, Arnaud, Belhadj, Karim, Fontan, Jean, Caillot, Denis, Stoppa, Anne-Marie, Attal, Michel, Facon, Thierry, Moreau, Philippe, Minvielle, Stephane, and Avet-Loiseau, Hervé

Published
2015
Full Text
View/download PDF

10. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

Author

Hebraud, Benjamin, Magrangeas, Florence, Cleynen, Alice, Lauwers-Cances, Valerie, Chretien, Marie-Lorraine, Hulin, Cyrille, Leleu, Xavier, Yon, Edwige, Marit, Gerald, Karlin, Lionel, Roussel, Murielle, Stoppa, Anne-Marie, Belhadj, Karim, Voillat, Laurent, Garderet, Laurent, Macro, Margaret, Caillot, Denis, Mohty, Mohamad, Facon, Thierry, Moreau, Philippe, Attal, Michel, Munshi, Nikhil, Corre, Jill, Minvielle, Stephane, and Avet-Loiseau, Herve

Published
2015
Full Text
View/download PDF

11. Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail RRMM patients: A multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).

Author

Leleu, Xavier, primary, Macro, Margaret, additional, Touzeau, Cyrille, additional, Mariette, Clara, additional, Manier, Salomon, additional, Brechignac, Sabine, additional, Vincent, Laure, additional, Hebraud, Benjamin, additional, Decaux, Olivier, additional, Schulmann, Samantha, additional, Lenoir, Caroline, additional, Godmer, Pascal, additional, Farge, Agathe, additional, Peyro Saint Paul, Laure, additional, and Parienti, Jean-Jacques, additional

Published
2022
Full Text
View/download PDF

12. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.

Author

UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Roussel, Murielle, Lauwers-Cances, Valérie, Macro, Margaret, Leleu, Xavier, Royer, Bruno, Hulin, Cyrille, Karlin, Lionel, Perrot, Aurore, Touzeau, Cyrille, Chrétien, Marie-Lorraine, Rigaudeau, Sophie, Dib, Mamoun, Nicolas-Virelizier, Emmanuelle, Escoffre-Barbe, Martine, Belhadj, Karim, Mariette, Clara, Stoppa, Anne-Marie, Araujo, Carla, Doyen, Chantal, Fontan, Jean, Kolb, Brigitte, Garderet, Laurent, Brechignac, Sabine, Malfuson, Jean-Valère, Jaccard, Arnaud, Lenain, Pascal, Borel, Cécile, Hebraud, Benjamin, Benbrahim, Omar, Dorvaux, Véronique, Manier, Salomon, Augeul-Meunier, Karine, Vekemans, Marie-Christiane, Randriamalala, Edouard, Chaoui, Driss, Caers, Jo, Chaleteix, Carine, Benboubker, Lofti, Vincent, Laure, Glaisner, Sylvie, Zunic, Patricia, Slama, Borhane, Eveillard, Jean-Richard, Humbrecht-Kraut, Catherine, Morel, Véronique, Mineur, Philippe, Eisenmann, Jean-Claude, Demarquette, Hélène, Richez, Valentine, Vignon, Marguerite, Caillot, Denis, Facon, Thierry, Moreau, Philippe, Colin, Anne-Laurène, Olivier, Pascale, Wuilleme, Soraya, Avet-Loiseau, Hervé, Corre, Jill, Attal, Michel, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Roussel, Murielle, Lauwers-Cances, Valérie, Macro, Margaret, Leleu, Xavier, Royer, Bruno, Hulin, Cyrille, Karlin, Lionel, Perrot, Aurore, Touzeau, Cyrille, Chrétien, Marie-Lorraine, Rigaudeau, Sophie, Dib, Mamoun, Nicolas-Virelizier, Emmanuelle, Escoffre-Barbe, Martine, Belhadj, Karim, Mariette, Clara, Stoppa, Anne-Marie, Araujo, Carla, Doyen, Chantal, Fontan, Jean, Kolb, Brigitte, Garderet, Laurent, Brechignac, Sabine, Malfuson, Jean-Valère, Jaccard, Arnaud, Lenain, Pascal, Borel, Cécile, Hebraud, Benjamin, Benbrahim, Omar, Dorvaux, Véronique, Manier, Salomon, Augeul-Meunier, Karine, Vekemans, Marie-Christiane, Randriamalala, Edouard, Chaoui, Driss, Caers, Jo, Chaleteix, Carine, Benboubker, Lofti, Vincent, Laure, Glaisner, Sylvie, Zunic, Patricia, Slama, Borhane, Eveillard, Jean-Richard, Humbrecht-Kraut, Catherine, Morel, Véronique, Mineur, Philippe, Eisenmann, Jean-Claude, Demarquette, Hélène, Richez, Valentine, Vignon, Marguerite, Caillot, Denis, Facon, Thierry, Moreau, Philippe, Colin, Anne-Laurène, Olivier, Pascale, Wuilleme, Soraya, Avet-Loiseau, Hervé, Corre, Jill, and Attal, Michel

Abstract

High-dose melphalan (HDM) and transplantation are recommended for eligible patients with multiple myeloma. No other conditioning regimen has proven to be more effective and/or safer. We previously reported in a phase 2 study that bortezomib can safely and effectively be combined with HDM (Bor-HDM), with a 32% complete response (CR) rate after transplantation. These data supported a randomized phase 3 trial. Randomization was stratified according to risk and response to induction: 300 patients were enrolled, and 154 were allocated to the experimental arm (ie, arm A) with bortezomib (1 mg/m2 intravenously [IV]) on days -6, -3, +1, and +4 and melphalan (200 mg/m2 IV) on day -2. The control arm (ie, arm B) consisted of HDM alone (200 mg/m2 IV). There were no differences in stringent CR + CR rates at day 60 posttransplant (primary end point): 22.1% in arm A vs 20.5% in arm B (P = .844). There were also no differences in undetectable minimum residual disease rates: 41.3% vs 39.4% (P = .864). Median progression-free survival was 34.0 months for arm A vs 29.6 months for arm B (adjusted HR, 0.82; 95% CI, 0.61-1.13; P = .244). The estimated 3-year overall survival was 89.5% in both arms (hazard ratio, 1.28; 95% CI, 0.62-2.64; P = .374). Sixty-nine serious adverse events occurred in 18.7% of Bor-HDM-treated patients (vs 13.1% in HDM-treated patients). The proportion of grade 3/4 AEs was similar within the 2 groups (72.0% vs 73.1%), mainly (as expected) blood and gastrointestinal disorders; 4% of patients reported grade 3/4 or painful peripheral neuropathy in arm A (vs 1.5% in arm B). In this randomized phase 3 study, a conditioning regimen with Bor-HDM did not improve efficacy end points or outcomes compared with HDM alone. The original trial was registered at www.clinicaltrials.gov as #NCT02197221.

Published
2022

13. Ixazomib and Daratumumab without Dexamethasone (I-Dara) in Elderly Frail RRMM Patients. a Multicenter Phase 2 Study (IFM 2018-02) of the Intergroupe Francophone Du Myélome (IFM)

Author

Macro, Magaret, primary, Touzeau, Cyrille, additional, Mariette, Clara, additional, Manier, Salomon, additional, Brechignac, Sabine, additional, Vincent, Laure, additional, Hebraud, Benjamin, additional, Decaux, Olivier, additional, Schulmann, Samantha, additional, Lenoir, Caroline Bureau, additional, Godmer, Pascal, additional, Parienti, Jean-Jacques, additional, and Leleu, Xavier, additional

Published
2021
Full Text
View/download PDF

15. Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison

Author

Moreau, Philippe, primary, Hebraud, Benjamin, additional, Facon, Thierry, additional, Leleu, Xavier, additional, Hulin, Cyrille, additional, Hashim, Mahmoud, additional, Hu, Yannan, additional, Caillot, Denis, additional, Benboubker, Lofti, additional, Zweegman, Sonja, additional, Merz, Maximilian, additional, Weisel, Katja, additional, Salwender, Hans, additional, Mai, Elias K, additional, Goldschmidt, Hartmut, additional, Bertsch, Uta, additional, Vanquickelberghe, Véronique, additional, Kampfenkel, Tobias, additional, Boer, Carla de, additional, Krotneva, Stanimira, additional, Proskorovsky, Irina, additional, He, Jianming, additional, Lam, Annette, additional, Lee, Charlene, additional, Cote, Sarah, additional, and Sonneveld, Pieter, additional

Published
2021
Full Text
View/download PDF

16. Functional Comparison between Healthy and Multiple Myeloma Adipose Stromal Cells

Author

Espagnolle, Nicolas, primary, Hebraud, Benjamin, additional, Descamps, Jean-Gérard, additional, Gadelorge, Mélanie, additional, Joubert, Marie-Véronique, additional, Ferreira, Laura Do Souto, additional, Roussel, Murielle, additional, Huynh, Anne, additional, Sensébé, Luc, additional, Casteilla, Louis, additional, Attal, Michel, additional, Avet-Loiseau, Hervé, additional, Deschaseaux, Frederic, additional, Bourin, Philippe, additional, and Corre, Jill, additional

Published
2020
Full Text
View/download PDF

17. Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma

Author

Roussel, Murielle, primary, Hebraud, Benjamin, additional, Hulin, Cyrille, additional, Perrot, Aurore, additional, Caillot, Denis, additional, Stoppa, Anne-Marie, additional, Macro, Margaret, additional, Escoffre, Martine, additional, Arnulf, Bertrand, additional, Belhadj, Karim, additional, Karlin, Lionel, additional, Garderet, Laurent, additional, Facon, Thierry, additional, Guo, Shien, additional, Weng, Josh, additional, Dhanasiri, Sujith, additional, Leleu, Xavier, additional, Moreau, Philippe, additional, and Attal, Michel, additional

Published
2020
Full Text
View/download PDF

18. Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03)

Author

Roussel, Murielle, primary, Hebraud, Benjamin, additional, Hulin, Cyrille, additional, Leleu, Xavier, additional, Facon, Thierry, additional, Boyle, Eileen, additional, Touzeau, Cyrille, additional, Pegourie, Brigitte, additional, Perrot, Aurore, additional, Stoppa, Anne-Marie, additional, Marolleau, Jean-Pierre, additional, Moreau, Philippe, additional, Avet-Loiseau, Herve, additional, Devlamynck, Laure, additional, Lauwers-Cances, Valerie, additional, and Attal, Michel, additional

Published
2019
Full Text
View/download PDF

19. A Prospective Phase II Trial of Lenalidomide and Dexamethasone in POEMS Syndrome

Author

Jaccard, Arnaud, primary, Karlin, Lionel, additional, Hebraud, Benjamin, additional, Frenzel, Laurent, additional, Choquet, Sylvain, additional, Mohty, Mohamad, additional, Dib, Mamoun, additional, Vincent, Laure, additional, Slama, Borhane, additional, Galicier, Lionel, additional, Tournilhac, Olivier, additional, Belhadj-Merzoug, Karim, additional, Moreau, Philippe, additional, Decaux, Olivier, additional, Benboubker, Lofti, additional, Caillot, Denis, additional, Fontan, Jean, additional, Maisonneuve, Hervé, additional, Bender, Sebastien, additional, Musset, Lucile, additional, and Fermand, Jean-Paul, additional

Published
2019
Full Text
View/download PDF

20. Integrated Analysis of Bortezomib-Lenalidomide-Dexamethasone vs Bortezomib-Thalidomide-Dexamethasone in Transplant-Eligible Newly Diagnosed Myeloma

Author

Rosinol, Laura, primary, Hebraud, Benjamin, additional, Oriol, Albert, additional, Colin, Anne-Laurène, additional, Tamayo, Rafael Ríos, additional, Hulin, Cyrille, additional, Blanchard, Maria Jesús, additional, Caillot, Denis, additional, Balari, Anna Sureda, additional, Hernandez, Miguel T., additional, Arnulf, Bertrand, additional, Mateos, Maria-Victoria, additional, Macro, Margaret, additional, San-Miguel, Jesus, additional, Belhadj, Karim, additional, Lahuerta, Juan-Jose, additional, Garelik, M. Brigid, additional, Blade, Joan, additional, Moreau, Philippe, additional, and Attal, Michel, additional

Published
2019
Full Text
View/download PDF

22. Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma

Author

Rosinol Dachs, Laura, primary, Hebraud, Benjamin, additional, Oriol, Albert, additional, Colin, Anne-Laurène, additional, Rios, Rafael, additional, Hulin, Cyrille, additional, Blanchard, Maria Jesús, additional, Caillot, Denis, additional, Sureda, Anna, additional, Hernández, Miguel T, additional, Arnulf, Bertrand, additional, Mateos, Maria-Victoria, additional, Macro, Margaret, additional, San-Miguel, Jesús F, additional, Belhadj, Karim, additional, Lahuerta, Juan Jose, additional, Chen, Guang, additional, Garelik, M. Brigid, additional, Bladé, Joan, additional, Moreau, Philippe, additional, and Attal, Michel, additional

Published
2018
Full Text
View/download PDF

23. The Impact of Lenalidomide, Bortezomib, and Dexamethasone Treatment on Health-Related Quality of Life in Transplant-Eligible Patients with Newly-Diagnosed Multiple Myeloma: Results from the IFM/DFCI 2009 Trial

Author

Roussel, Murielle, primary, Hebraud, Benjamin, additional, Hulin, Cyrille, additional, Perrot, Aurore, additional, Caillot, Denis, additional, Macro, Margaret, additional, Arnulf, Bertrand, additional, Belhadj, Karim, additional, Garderet, Laurent, additional, Facon, Thierry, additional, Guo, Shien, additional, Altincatal, Arman, additional, Dhanasiri, Sujith, additional, Leleu, Xavier, additional, Moreau, Philippe, additional, and Attal, Michel, additional

Published
2018
Full Text
View/download PDF

24. Light Chain Escape in Multiple Myeloma

Author

Dejoie, Thomas, primary, Fouquet, Guillemette, additional, Hulin, Cyrille, additional, Roussel, Murielle, additional, Hebraud, Benjamin, additional, Karlin, Lionel, additional, Kolb, Brigitte, additional, Araujo, Carla, additional, Meuleman, Nathalie, additional, Tiab, Mourad, additional, Malfuson, Jean Valère, additional, Bourquard, Pascal, additional, Lenain, Pascal, additional, Jaccard, Arnaud, additional, Belhadj, Karim, additional, Lepeu, Gérard, additional, Chretien, Marie Lorraine, additional, Caillot, Denis, additional, Fontan, Jean, additional, Rodon, Philippe, additional, Schmitt, Anna, additional, Voillat, Laurent, additional, Cereja, Sophie, additional, Pegourie, Brigitte, additional, Kuhnowski, Frederique, additional, Rigaudeau, Sophie, additional, Decaux, Olivier, additional, Humbrecht-Kraut, Catherine, additional, Frayfer, Jamilé, additional, Garderet, Laurent, additional, Roos-Weil, Damien, additional, Eisenmann, Jean Claude, additional, Dorvaux, Veronique, additional, Voog, Eric G., additional, Mathiot, Claire, additional, Fermand, Jean-Paul, additional, Facon, Thierry, additional, Avet-Loiseau, Hervé, additional, Harousseau, Jean Luc, additional, Moreau, Philippe, additional, Attal, Michel, additional, and Leleu, Xavier, additional

Published
2018
Full Text
View/download PDF

25. Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria

Author

Fouquet, Guillemette, primary, Snell, Kym IE, additional, Guidez, Stéphanie, additional, Schraen, Susanna, additional, Boyle, Eileen, additional, Renaud, Loïc, additional, Desmier, Déborah, additional, Machet, Antoine, additional, Moya, Niels, additional, Systchenko, Thomas, additional, Gruchet, Cécile, additional, Decaux, Olivier, additional, Arnulf, Bertrand, additional, Fohrer, Cécile, additional, Richez, Valentine, additional, Kolb, Brigitte, additional, Macro, Margaret, additional, Karlin, Lionel, additional, Royer, Bruno, additional, Pegourie, Brigitte, additional, Hebraud, Benjamin, additional, Caillot, Denis, additional, Perrot, Aurore, additional, Moreau, Philippe, additional, Facon, Thierry, additional, Avet-Loiseau, Hervé, additional, Dejoie, Thomas, additional, Hulin, Cyrille, additional, Harding, Stephen, additional, and Leleu, Xavier, additional

Published
2017
Full Text
View/download PDF

26. Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma

Author

Kendrick, Felicity, primary, Evans, Neil D., additional, Arnulf, Bertrand, additional, Avet-Loiseau, Hervé, additional, Decaux, Olivier, additional, Dejoie, Thomas, additional, Fouquet, Guillemette, additional, Guidez, Stéphanie, additional, Harel, Stéphanie, additional, Hebraud, Benjamin, additional, Javaugue, Vincent, additional, Richez, Valentine, additional, Schraen, Susanna, additional, Touzeau, Cyrille, additional, Moreau, Philippe, additional, Leleu, Xavier, additional, Harding, Stephen, additional, and Chappell, Michael J., additional

Published
2017
Full Text
View/download PDF

27. Positivity Rates of Tests Used at Immune Thrombocytopenia Diagnosis to Detect Associated Diseases. a Prospective Multicenter Cohort Study of 218 Patients

Author

Moulis, Guillaume, primary, Comont, Thibault, additional, Germain, Johanne, additional, Essilini, Anaïs, additional, Brun, Natacha, additional, Dingremont, Claire, additional, Castel, Brice, additional, Montané de la Roque, Philippe, additional, Madaule, Serge, additional, Sailler, Laurent, additional, Prudhomme, Laurent, additional, Arista, Sophie, additional, Balardy, Laurent, additional, Gaches, Francis, additional, Hebraud, Benjamin, additional, Borel, Cecile, additional, Sire, Stéphane, additional, Carreiro, Miguel, additional, Martin-Blondel, Guillaume, additional, Alric, Laurent, additional, Giraud, Patrick, additional, Lapeyre-Mestre, Maryse, additional, Beyne-Rauzy, Odile, additional, and Adoue, Daniel, additional

Published
2016
Full Text
View/download PDF

28. Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: High-Dose Cyclophosphamide Versus Plerixafor. on Behalf of IFM

Author

van de Wyngaert, Zoe, primary, Azar, Nabih, additional, Lenain, Pascal, additional, Macro, Margaret, additional, Bourhis, Jean-Henri, additional, Garderet, Laurent, additional, Jaccard, Arnaud, additional, Karlin, Lionel, additional, Giraud, Christine, additional, Guidez, Stéphanie, additional, Hebraud, Benjamin, additional, Roussel, Muriel, additional, Marit, Gerald, additional, Hulin, Cyrille, additional, Deconinck, Eric, additional, Attal, Michel, additional, Moreau, Philippe, additional, Caillot, Denis, additional, Limat, Samuel, additional, Leleu, Xavier, additional, and Chretien, Marie-Lorraine, additional

Published
2016
Full Text
View/download PDF

29. Interest in Initiating Corticosteroids By Intravenous Methylprednisolone at Standard Dose in Newly Diagnosed Immune Thrombocytopenia Adults: Results of the Prospective Carmen Registry

Author

Essilini, Anaïs, primary, Comont, Thibault, additional, Germain, Johanne, additional, Brun, Natacha, additional, Dingremont, Claire, additional, Castel, Brice, additional, Montané de la Roque, Philippe, additional, Madaule, Serge, additional, Sailler, Laurent, additional, Prudhomme, Laurent, additional, Arista, Sophie, additional, Balardy, Laurent, additional, Gaches, Francis, additional, Hebraud, Benjamin, additional, Borel, Cecile, additional, Sire, Stéphane, additional, Carreiro, Miguel, additional, Martin-Blondel, Guillaume, additional, Alric, Laurent, additional, Giraud, Patrick, additional, Lapeyre-Mestre, Maryse, additional, Beyne-Rauzy, Odile, additional, Adoue, Daniel, additional, and Moulis, Guillaume, additional

Published
2016
Full Text
View/download PDF

31. Phase 1 dose-escalation study of BI 836909, an anti-BCMA bi-specific T-cell engager, in relapsed and/or refractory multiple myeloma (RRMM).

Author

Topp, Max S., primary, Attal, Michel, additional, Langer, Christian, additional, Moreau, Philippe, additional, Facon, Thierry, additional, Düll, Johannes, additional, Hebraud, Benjamin, additional, Gomez-Roca, Carlos, additional, Munzert, Gerd Michael, additional, Gracien, Edith, additional, Zugmaier, Gerhard, additional, and Einsele, Hermann, additional

Published
2016
Full Text
View/download PDF

32. Impact of Poor Tolerance and Discontinuation of the Dexamethasone during Treatment with Lenalidomide-Dexamethasone in Relapsed and Refractory Multiple Myeloma

Author

Guidez, Stéphanie, primary, Fouquet, Guillemette, additional, Demarquette, Hélène, additional, Nudel, Morgane, additional, Boyle, Eileen, additional, Chretien, Marie Lorraine, additional, Caillot, Denis, additional, Karlin, Lionel, additional, Hulin, Cyrille, additional, Decaux, Olivier, additional, Arnulf, Bertrand, additional, Fohrer, Cécile, additional, MACRO, Margaret, additional, Lancesseur, Charles, additional, Roussel, Murielle, additional, Hebraud, Benjamin, additional, Facon, Thierry, additional, and Leleu, Xavier, additional

Published
2015
Full Text
View/download PDF

33. Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).

Author

Touzeau, Cyrille, Leleu, Xavier P, Mariette, Clara, Manier, Salomon, Brechignac, Sabine, Vincent, Laure, Hebraud, Benjamin, Decaux, Olivier, Schulmann, Samantha, Lenoir, Caroline, Godmer, Pascal, Farge, Agathe, Peyro Saint Paul, Laure, Parienti, Jean-Jacques, and Macro, Margaret

Published
2023
Full Text
View/download PDF

34. Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02)

Author

Roussel, Murielle, Hebraud, Benjamin, Lauwers-Cances, Valerie, Macro, Margaret, Leleu, Xavier, Hulin, Cyrille, Karlin, Lionel, Royer, Bruno, Perrot, Aurore, Moreau, Philippe, Caillot, Denis, Rigaudeau, Sophie, Dib, Mamoun, Nicolas-Virelizier, Emmanuelle, Escoffre-Barbe, Martine, Belhadj, Karim, Pegourie, Brigitte, Stoppa, Anne-Marie, Araujo, Carla, Doyen, Chantal, Fontan, Jean, Kolb, Brigitte, Garderet, Laurent, Brechignac, Sabine, Malfuson, Jean Valere, Dorvaux, Veronique, Lenain, Pascal, Benbrahim, Omar, Jaccard, Arnaud, Borel, Cecile, Avet Loiseau, Herve, and Attal, Michel

Published
2017
Full Text
View/download PDF

35. Outcome at first relapse after frontline RVD regimen plus lenalidomide maintenance in transplant eligible MM patients.

Author

Roussel, Murielle, primary, Hebraud, Benjamin, additional, Caillot, Denis, additional, Leleu, Xavier, additional, Macro, Margaret, additional, Hulin, Cyrille, additional, Chaleteix, Carine, additional, Escoffre Barbe, Martine, additional, Karlin, Lionel, additional, Marit, Gerald, additional, Garderet, Laurent, additional, Pegourie, Brigitte, additional, Stoppa, Anne-Marie, additional, Lenain, Pascal, additional, Royer, Bruno, additional, Avet-Loiseau, Herve, additional, and Attal, Michel, additional

Published
2015
Full Text
View/download PDF

38. Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome

Author

Roussel, Murielle, primary, Lauwers-Cances, Valérie, additional, Robillard, Nelly, additional, Hulin, Cyrille, additional, Leleu, Xavier, additional, Benboubker, Lotfi, additional, Marit, Gérald, additional, Moreau, Philippe, additional, Pegourie, Brigitte, additional, Caillot, Denis, additional, Fruchart, Christophe, additional, Stoppa, Anne-Marie, additional, Gentil, Catherine, additional, Wuilleme, Soraya, additional, Huynh, Anne, additional, Hebraud, Benjamin, additional, Corre, Jill, additional, Chretien, Marie-Lorraine, additional, Facon, Thierry, additional, Avet-Loiseau, Hervé, additional, and Attal, Michel, additional

Published
2014
Full Text
View/download PDF

39. Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation

Author

Fouquet, Guillemette, primary, Hebraud, Benjamin, additional, Garciaz, Sylvain, additional, Stoppa, Anne Marie, additional, Roussel, Murielle, additional, Caillot, Denis, additional, Chrétien, Marie Lorraine, additional, Arnulf, Bertrand, additional, Szalat, Raphael, additional, Garderet, Laurent, additional, Benajiba, Lina, additional, Pegourie, Brigitte, additional, Regny, Caroline, additional, Royer, Bruno, additional, Caulier, Alexis, additional, Touzeau, Cyrille, additional, Tessoulin, Benoit, additional, Fermand, Jean Paul, additional, Facon, Thierry, additional, Attal, Michel, additional, Loiseau, Hervé Avet, additional, Moreau, Philippe, additional, and Leleu, Xavier, additional

Published
2014
Full Text
View/download PDF

40. Impact Of Consolidation With Bortezomib-Thalidomide-Dexamethasone (VTd) Upfront In Multiple Myeloma (MM) With Partial Response (PR) At Completion Of Induction With Vtd

Author

Leleu, Xavier, primary, Fouquet, Guillemette, additional, Hebraud, Benjamin, additional, Garciaz, Sylvain, additional, Stoppa, Anne-Marie, additional, Roussel, Murielle, additional, Caillot, Denis, additional, Chretien, Marie-Lorraine, additional, Arnulf, Bertrand, additional, Szalat, Raphael, additional, Garderet, Laurent, additional, Benajiba, Lina, additional, Pegourie, Brigitte, additional, Regny, Caroline, additional, Royer, Bruno, additional, Caulier, Alexis, additional, Touzeau, Cyrille, additional, Tessoulin, Benoit, additional, Fermand, Jean Paul, additional, Facon, Thierry, additional, Attal, Michel, additional, Avet-Loiseau, Herve, additional, and Moreau, Philippe, additional

Published
2013
Full Text
View/download PDF

41. Myeloma: a subclonal disease?

Author

Chretien, Marie-Lorraine, additional, Hebraud, Benjamin, additional, Roussel, Murielle, additional, Attal, Michel, additional, Corre, Jill, additional, and Avet-Loiseau, Hervé, additional

Published
2013
Full Text
View/download PDF

42. Lost and Gain of t(4;14) and t(11;14) in Multiple Myeloma Patients Between Relapse and diagnosis: An Illustration of Clonal Dynamic During Disease Course. an IFM Study

Author

Hebraud, Benjamin, primary, Caillot, Denis, additional, Corre, Jill, additional, Marit, Gerald, additional, Hulin, Cyrille, additional, Leleu, Xavier, additional, Wetterwald, Marc, additional, Dib, Mamoun, additional, Rodon, Philippe, additional, Voillat, Laurent, additional, Royer, Bruno, additional, Voog, Eric G., additional, Stoppa, Anne-Marie, additional, Garderet, Laurent, additional, Kolb, Brigitte, additional, Maigre, Michel, additional, Nadine, Boullanger FOW HENG, additional, Allangba, Olivier, additional, Facon, Thierry, additional, Mathiot, Claire, additional, Attal, Michel, additional, Moreau, Philippe, additional, and avet-Loiseau, Herve, additional

Published
2012
Full Text
View/download PDF

43. Are Stromal Cells of Adipose Tissue From Multiple Myeloma Patients Are Normal ? A Comparison of Adipose Derived Stromals Cells From Healthy Donors and Multiple Myeloma Patients

Author

Hebraud, Benjamin, primary, Labat, Elodie, additional, Espagnolle, Nicolas, additional, Gadelorge, Melanie, additional, Casteilla, Louis, additional, Sensebé, Luc, additional, Roussel, Murielle, additional, Huynh, Anne, additional, Joubert, marie-Veronique, additional, Corre, Jill, additional, avet-Loiseau, Herve, additional, Attal, Michel, additional, and Bourin, Philippe, additional

Published
2012
Full Text
View/download PDF

44. 1p22 and 1p32 Deletions Are Independent Prognosis Factors in Young Patients with Myeloma: The IFM Experience On 1195 Patients

Author

Hebraud, Benjamin, primary, Leleu, Xavier, additional, lauwers-Cances, Valerie, additional, Roussel, Murielle, additional, Marit, Gerald, additional, Karlin, Lionel, additional, Hulin, Cyrille, additional, Gentil, Catherine, additional, Guilhot, Francois, additional, Garderet, Laurent, additional, Lamy, Thierry, additional, Brechignac, Sabine, additional, Pegourie, Brigitte, additional, Jaubert, Jerome, additional, Dib, Mamoun, additional, Stoppa, Anne-Marie, additional, Sebban, Catherine, additional, Fohrer, Cecile, additional, Fontan, Jean, additional, Fruchart, Christophe, additional, Bouscary, Didier, additional, Corront, Bernadette, additional, Lepeu, Gerard, additional, Corre, Jill, additional, Facon, Thierry, additional, Attal, Michel, additional, Moreau, Philippe, additional, and avet-Loiseau, Herve, additional

Published
2012
Full Text
View/download PDF

45. Consolidation with Vtd Significantly Improves the Complete Remission (CR) Rate Following Vtd Induction and Single Autologous Stem Cell Transplantation (auto) in Multiple Myeloma (MM).

Author

Leleu, Xavier, primary, Hebraud, Benjamin, additional, Fouquet, Guillemette, additional, Roussel, Murielle, additional, Caillot, Denis, additional, Chretien, Marie-Lorraine, additional, Arnulf, Bertrand, additional, Szalat, Raphael, additional, Garderet, Laurent, additional, Benajiba, Lina, additional, Pegourie, Brigitte, additional, Regny, Caroline, additional, Royer, Bruno, additional, Caulier, Alexis, additional, Stoppa, Anne-Marie, additional, Garciaz, Sylvain, additional, Touzeau, Cyrille, additional, Fermand, Jean-Paul, additional, Facon, Thierry, additional, Attal, Michel, additional, and Moreau, Philippe, additional

Published
2012
Full Text
View/download PDF

48. Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma.

Author

Corre, Jill, Labat, Elodie, Espagnolle, Nicolas, Hebraud, Benjamin, Avet-Loiseau, Herve, Roussel, Murielle, Huynh, Anne, Gadelorge, Melanie, Cordelier, Pierre, Klein, Bernard, Moreau, Philippe, Facon, Thierry, Fournie, Jean-Jacques, Attal, Michel, and Bourin, Philippe

Subjects
*BIOACTIVE compounds, *MESENCHYMAL stem cells, *MULTIPLE myeloma, *CANCER cell growth, *BONE marrow cells
Abstract

Overexpression of growth differentiation factor 15 (GDF15) by bone marrow mesenchymal stem cells occurs widely in patients with multiple myeloma, but the pathophysiologic effects of GDF15 in this setting remain undefined. GDF15 has been described in numerous solid tumors but never in hematologic malignancies. In this study, we report that GDF15 significantly increases survival of stroma-dependent multiple myeloma cells including primary multiple myeloma cells. In particular, GDF15 conferred resistance to melphalan, bortezomib, and to a lesser extent, lenalidomide in both stroma-dependent and stroma-independent multiple myeloma cells. Akt-dependent signaling was critical to mediate the effects of GDF15, whereas Src and extracellular signal-regulated kinase 1/2 signaling pathways were not involved. Given these results, we tested the clinical significance of plasma concentrations of GDF15 (pGDF15) in 131 patients with multiple myeloma and found that it correlated with disease prognosis. Specifically, patients with high levels of pGDF15 had lower probabilities of event-free and overall survival 30 months after diagnosis than patients with low pGDF15 levels. Our findings suggest that tumor microenvironment-derived GDF15 is a key survival and chemoprotective factor for multiple myeloma cells, which is pathophysiologically linked to both initial parameters of the disease as well as patient survival. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

49. Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria.

Author

Fouquet G, Snell KI, Guidez S, Schraen S, Boyle E, Renaud L, Desmier D, Machet A, Moya N, Systchenko T, Gruchet C, Decaux O, Arnulf B, Fohrer C, Richez V, Kolb B, Macro M, Karlin L, Royer B, Pegourie B, Hebraud B, Caillot D, Perrot A, Moreau P, Facon T, Avet-Loiseau H, Dejoie T, Hulin C, Harding S, and Leleu X

Subjects
Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma blood, Multiple Myeloma pathology, Prognosis, Remission Induction, Survival Rate, Biomarkers, Tumor blood, Immunoassay standards, Immunoglobulin Heavy Chains blood, Immunoglobulin Light Chains blood, Monitoring, Immunologic methods, Multiple Myeloma mortality
Abstract

Automated serum heavy + light chain (HLC) immunoassays can measure the intact immunoglobulins of each light chain type separately. We though to compare HLC assays with electrophoretic techniques in determining International Myeloma Working Group (IMWG) response criteria. 114 myeloma patients from 2 trials were included. HLC measurements were made utilizing archived sera and response assessments compared with those based on electrophoretic analysis at the time of the trials. Assessments at ∼90 days and maximal response were compared as was the power of the 2 techniques for predicting later responses, overall survival, and progression. The kappa statistic indicated good agreement between the 2 methods for determining IMWG response criteria, although HLC measurements might give better predictions of subsequent responses and frequently gave an earlier indication of change. HLC measurements could represent an alternative to electrophoretic techniques in determining IMWG response. Validation with a greater range of patient responses is needed for confirmation.

Published
2018
Full Text
View/download PDF

50. Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients.

Author

Chretien ML, Hebraud B, Cances-Lauwers V, Hulin C, Marit G, Leleu X, Karlin L, Roussel M, Stoppa AM, Guilhot F, Lamy T, Garderet L, Pegourie B, Dib M, Sebban C, Lenain P, Brechignac S, Royer B, Wetterwald M, Legros L, Orsini-Piocelle F, Voillat L, Delbrel X, Caillot D, Macro M, Facon T, Attal M, Moreau P, Avet-Loiseau H, and Corre J

Subjects
Adult, Age Factors, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Dexamethasone therapeutic use, Doxorubicin therapeutic use, Humans, Induction Chemotherapy, Middle Aged, Multiple Myeloma mortality, Prognosis, Retrospective Studies, Treatment Outcome, Vincristine therapeutic use, Young Adult, Antineoplastic Agents, Alkylating administration & dosage, Melphalan administration & dosage, Multiple Myeloma drug therapy
Abstract

Age is a strong prognostic factor in multiple myeloma. The overall survival is shorter in patients older than 66 years, and even shorter in those older than 75 years. Whether age is also a prognostic parameter in patients younger than 66 years treated homogeneously with intensive approaches is unknown. To address this issue, we retrospectively analyzed a series of 2316 patients treated homogeneously with 3-4 cycles of induction chemotherapy followed by a high-dose melphalan course, without any consolidation or maintenance. We show that patients older than 60 years have a statistically significant shorter overall survival. The analysis of prognostic parameters did not show a higher incidence of high-risk cytogenetics, but a higher incidence of International Staging System (ISS) stages 2 and 3, mainly due to higher β2-microglobulin levels. This study is the first to demonstrate the impact of age in the outcome of 'young' patients with multiple myeloma, and suggests that this parameter should be included in the stratification factors for future prospective clinical trials., (Copyright© Ferrata Storti Foundation.)

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results